Loading organizations...
Sandstone Diagnostics has raised $8.0M across 2 funding rounds.
Sandstone Diagnostics has raised $8.0M in total across 2 funding rounds.
Sandstone Diagnostics has raised $8.0M in total across 2 funding rounds.
Sandstone Diagnostics's investors include Astia, Broadway Angels, Celesta, Element Partners, Fuel Capital, Lightbank, Montage Ventures, Threshold Ventures, Leah Busque.
Sandstone Diagnostics is a healthtech startup founded in 2012 as a spin-out from Sandia National Laboratories, developing portable, lightweight centrifuge platforms for rapid point-of-care diagnostic testing.[1][2][3] The company builds products like the FDA-cleared Trak® Male Fertility Testing System and Torq™ technology for zero-delay plasma separation, serving patients, clinicians, and healthcare providers by enabling on-site sample processing of blood, semen, and other fluids.[1][2][3] It solves key problems in traditional lab-based diagnostics—such as delays, sample degradation, high costs, and limited access—by bringing centrifuge technology directly to the point of care, improving sample stability, test accuracy, and decentralization, with reported $500K in trailing twelve-month revenue and applications now available via GSA Schedule for government use.[2][3]
Growth momentum includes expanding distribution for Trak®, advancing plasma separation tech for automated blood prep at collection, and participation in initiatives like Stanford StartX Med COVID-19 Task Force and StartUp Health, positioning it in the burgeoning point-of-care diagnostics market.[2][3]
Sandstone Diagnostics emerged in April 2012 from Sandia National Labs, where government scientists pioneered miniaturized centrifuge technology to apply centrifugal force efficiently with reduced size and power.[1][2][3] Key founders include Greg J. Sommer (Founder & CSO, PhD engineer with 10+ years in diagnostic solutions), Ulrich Y. Schaff (Founder & CTO, lead inventor of core tech, PhD biotech expert), Sara Naab (Founder & Director of Marketing, serial entrepreneur and 2013 Female Entrepreneur of the Year), and Paul Manners (CFO, healthcare finance veteran).[2] The idea stemmed from lab innovations to "bring the centrifuge to the patient," humanizing diagnostics by enabling home or bedside testing; early traction came via FDA clearance for Trak® and pivots to plasma tech amid growing POC demand.[1][2][3]
Sandstone rides the point-of-care diagnostics trend, accelerated by pandemics like COVID-19, where its tech supported Stanford StartX Med Task Force efforts for decentralized testing.[3] Timing aligns with market forces favoring rapid, lab-independent diagnostics—driven by telemedicine growth, supply chain vulnerabilities, and demand for at-home health monitoring amid aging populations and chronic disease rises.[2][3] It influences the ecosystem by enabling "ubiquitous high-quality lab testing," lowering barriers in healthtech for fertility, blood analysis, and beyond, while competing in a medical devices sector projected for expansion via portable biotech spin-outs.[1][4]
Sandstone is poised to scale its centrifuge platforms amid POC diagnostics boom, potentially expanding Trak® distribution, Torq™ government contracts, and new apps like pandemic response or chronic monitoring.[2][3] Trends like AI-enhanced testing and global health equity will shape its path, with influence evolving via partnerships (e.g., StartUp Health) and revenue growth beyond $500K TTM. As a Sandia spin-out miniaturizing core lab tech, it exemplifies how national lab innovations propel accessible healthcare, tying back to its mission of putting "a new spin on healthcare."[1][2]
Sandstone Diagnostics has raised $8.0M across 2 funding rounds. Most recently, it raised $6.0M Series A in January 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2018 | $6.0M Series A | Astia, Broadway Angels | |
| Nov 1, 2016 | $2.0M Venture Round | Broadway Angels, Celesta, Element Partners, Fuel Capital, Lightbank, Montage Ventures, Threshold Ventures, Leah Busque |